Literature DB >> 28107562

Hydroxycarbamide for patients with silent cerebral infarcts: outcomes and patient preference.

Tullia Rushton1, Inmaculada Aban2, Daniel Young3, Thomas Howard1, Lee Hilliard1, Jeffrey Lebensburger1.   

Abstract

Entities:  

Keywords:  hydroxycarbamide; patient preference; sickle cell disease; silent infarct; stroke

Mesh：

Substances：

Year:  2017        PMID： 28107562     DOI： 10.1111/bjh.14526

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

Review 1.  Advances in Understanding Ischemic Stroke Physiology and the Impact of Vasculopathy in Children With Sickle Cell Disease.

Authors:  Kristin P Guilliams; Melanie E Fields; Michael M Dowling
Journal:  Stroke       Date:  2019-02       Impact factor: 7.914

2.  Progression of central nervous system disease from pediatric to young adulthood in sickle cell anemia.

Authors:  Grace Champlin; Scott N Hwang; Andrew Heitzer; Juan Ding; Lisa Jacola; Jeremie H Estepp; Winfred Wang; Kenneth I Ataga; Curtis L Owens; Justin Newman; Allison A King; Robert Davis; Guolian Kang; Jane S Hankins
Journal:  Exp Biol Med (Maywood)       Date:  2021-08-18

3.  Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia.

Authors:  Kristine Karkoska; Charles T Quinn; Omar Niss; Amanda Pfeiffer; Min Dong; Alexander A Vinks; Patrick T McGann
Journal:  Am J Hematol       Date:  2021-02-19       Impact factor: 10.047

4.  Hydroxyurea reduces cerebral metabolic stress in patients with sickle cell anemia.

Authors:  Melanie E Fields; Kristin P Guilliams; Dustin Ragan; Michael M Binkley; Amy Mirro; Slim Fellah; Monica L Hulbert; Morey Blinder; Cihat Eldeniz; Katie Vo; Joshua S Shimony; Yasheng Chen; Robert C McKinstry; Hongyu An; Jin-Moo Lee; Andria L Ford
Journal:  Blood       Date:  2019-03-11       Impact factor: 22.113

Review 5.  Why, Who, When, and How? Rationale for Considering Allogeneic Stem Cell Transplantation in Children with Sickle Cell Disease.

Authors:  Françoise Bernaudin
Journal:  J Clin Med       Date:  2019-09-22       Impact factor: 4.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.